Jasper Therapeutics to Present at May Investor Conferences

Jasper Therapeutics, Inc., a biotechnology firm headquartered in Redwood City, California, has scheduled presentations at two significant investor conferences in May 2024. Jasper, trading on Nasdaq under the symbol JSPR, is dedicated to the development of briquilimab, an innovative antibody therapy aimed at c-Kit (CD117). This therapy targets diseases driven by mast cells, such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU).

The first event is the Capital One Securities Biotech/Biopharma Disruptors Event, taking place on May 14, 2024. Jasper will participate in a panel discussion titled "New Dermatology Treatments" at 2:45 p.m. EDT on the same day. This discussion will provide insights into Jasper's advancements and future plans for briquilimab.

Following this, Jasper will present at the 2024 RBC Capital Markets Global Healthcare Conference, scheduled for May 14-15, 2024. Jasper's presentation, in the format of a fireside chat, is set for May 15 at 3:35 p.m. EDT. This chat will be streamed live on Jasper's Investor Relations website, with a replay available for 30 days post-event.

Jasper Therapeutics is a clinical-stage biotechnology enterprise focused on advancing briquilimab, a monoclonal antibody, for treating chronic mast cell diseases and as a conditioning agent for stem cell transplants in rare diseases. Chronic urticaria and myelodysplastic syndromes (MDS) represent primary target conditions for briquilimab, which has shown promising efficacy and safety in over 145 participants, including healthy volunteers and patients with various conditions. These conditions include severe combined immunodeficiency (SCID), acute myeloid leukemia, MDS, Fanconi anemia (FA), and sickle cell disease (SCD).

Jasper's development efforts are centered on leveraging briquilimab's capabilities to provide therapeutic benefits across a range of diseases. Data thus far underscore its potential as a robust treatment option for patients with chronic urticaria and other ailments necessitating effective therapeutic interventions. The company's commitment to addressing unmet medical needs is evident in its strategic participation in key industry conferences to highlight its research progress and engage with the broader medical and investor communities.

The upcoming conferences in May represent crucial opportunities for Jasper to showcase its advancements and ongoing research in the field of biotechnology. By participating in these events, Jasper aims to elucidate the therapeutic potential of briquilimab and its broader implications for treating chronic mast cell-driven diseases and facilitating successful stem cell transplants.

These engagements underscore Jasper's proactive approach to communicating its scientific achievements and future directions to a diverse audience, including investors, healthcare professionals, and industry stakeholders. With a focus on innovative treatment options, Jasper continues to spearhead efforts to improve patient outcomes through advanced biotechnological solutions.